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• Risk factors for prostate cancer include only: age, race 
and family history.
• In the US 180,000 new cases of prostate cancer and 
26,000 deaths per year.
• Low sensitivity of screening tests leads to unnecessary 
procedures and complications.
• Clinically insignificant cancer is often diagnosed on 
autopsy.
• Risk factors for metabolic syndrome include high fat low 
fiber diet and sedentary lifestyle among others.
• Metabolic syndrome is defined as having 3 oft of 5 
abnormal: Triglycerides, serum glucose, HDL, blood 
pressure and weight. 
Research Question
Literature Review
Applicability to Clinical 
Practice
Results
• This figure is a graphical representation of the 
relationship between metabolic syndrome components 
and both overall prostate cancer and death from prostate 
cancer. 
• Model 1 Corrected for random error using the regression 
dilution ratio. 
• Model 2 corrected for random error using regression 
calibration.
• Composite score is as compilation of the z scores 
calculated for each individual component.
• Prostate cancer and metabolic syndrome are both 
prevalent among men in developed countries with peak 
incidence after age 50. 
• Prostate cancer has no known modifiable risk factors.
• Most risk factors for metabolic syndrome are modifiable. 
• If metabolic syndrome is identified as contributing to the 
risk of prostate cancer it would give an element of self 
determination to men at risk for prostate cancer.
• Past studies provide conflicting results in the correlation 
between these two conditions.
• A literature review was performed to evaluate 
consistencies in current literature.  
• Metabolic syndrome or its components do not increase the 
risk of developing overall prostate cancer. 
• Metabolic syndrome does increase mortality from prostate 
cancer. 
• Men with metabolic syndrome are found to have higher 
grades of disease upon diagnosis of prostate cancer
• Are men with a diagnosis of metabolic syndrome at 
increased risk for developing prostate cancer compared to 
men without.?
•Prostate cancer is defined as overall cases.
•No differentiation is made between high and low grade 
cancer based of Gleason score or presence of 
symptoms. 
• Do any of the individual components of metabolic syndrome 
increase the risk for developing prostate cancer?
•Metabolic syndrome components include
•Above normal serum triglyceride levels
•Above normal serum glucose levels
•Below normal serum HDL
•Elevated blood pressure
•Above normal weight
• Metabolic syndrome does not increase the risk of 
developing cancer. Diabetes may be protective against 
developing prostate cancer (Wallner, 2010).
• There is no significant correlation found between metabolic 
syndrome and prostate cancer (Lawrence,2012).
• No individual components of metabolic syndrome or any 
composite grouping of them increase the risk of prostate 
cancer, increased mortality found (Haggstrom, 2012).
• Metabolic syndrome specifically including hypertension 
increased the risk of prostate cancer. Hypertension alone 
does not increase risk, metabolic syndrome without 
hypertension does not increase risk (Radisauskas, 2016).
• Hypertension does increase the risk of overall prostate 
cancer (Liang, 2016).
• Men with metabolic syndrome have greater risk of high 
grade prostate cancer than those without (Zhang, 2015)
• No individual component of metabolic syndrome increases 
the risk of prostate cancer (Bhindi, 2014).
• Men with metabolic syndrome have higher grades of 
disease upon prostate biopsy (De Nunzio, 2011).
• One metabolic syndrome component was protective 
against prostate cancer, 2 or more components were 
associated with higher grades of cancer on diagnosis 
(Sourbeer, 2014).
• Practitioners should not alter their practice from established 
guidelines to screen for prostate cancer in the presence of 
metabolic conditions. 
• Current prostate cancer screening guidelines.
•American College of Physicians
•Shared decision making age 50-60 with >15 years 
of life expectancy.
•American Cancer Society
•Shared Decision Making at age 50 for men of 
average risk.
• Providers should be mindful that men with metabolic 
disorders will likely have more advanced prostate cancer 
when diagnosed than men without.
• Be mindful of the of the importance of preventative medicine 
when caring for patients with complex medical histories. 
• Prostate cancer screening requires shared decision making. 
Knowledge of advanced disease should be part of the 
conversation about screening. 
• Due to inconsistencies in the definition of metabolic 
syndrome, cross study comparisons must be qualitative 
which leads to inaccuracies.
• For example one study will classify hypertension by 
blood pressure measurement while others use a 
prescription of antihypertensive medication to 
define it. 
• The strongest evidence available indicates no positive 
correlation between metabolic syndrome as a whole and 
overall prostate cancer. 
• Studies indicating individual components of metabolic 
syndrome increase the risk of prostate cancer have 
weaknesses which undermine their results, coupled with 
weak statistical correlations.
• Good quality evidence supports a correlation between the 
number of metabolic components a man has and the 
grade of prostate cancer he has upon diagnosis. 
• This is further supported by strong evidence for 
increased mortality from prostate cancer among 
men with metabolic syndrome or components. 
• Further analysis is needed to investigate the degree to 
which diabetes is protective against prostate cancer. 
Statement of the Problem
• Both conditions are found in similar cohorts.
• Metabolic syndrome has been proven modifiable through 
lifestyle modification while Prostate Cancer is unavoidable.
• Past literature makes differing conclusions on the 
correlation between the two. 
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